Phase 2 Evidence and Impact Analysis
Article 1 — Hao et al. — AI imaging models for hemorrhagic transformation after thrombectomy (PMID 42978651)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | AI prediction of HT post-MT is an active but not nascent area; meta-analysis aggregates existing work rather than introducing new methods |
| Clinical Relevance | 7 | HT is a feared, often-fatal complication; a validated prediction tool could change peri-procedural management |
| Population Reach | 6 | Stroke is globally common; MT is increasingly used but still limited to stroke-centre-capable hospitals |
| Implementation Speed | 5 | AI imaging tools require integration into radiology/PACS workflows, regulatory clearance, and site validation |
| Evidence Strength | 7 | Systematic review/meta-analysis of 11 studies (N=3,541); heterogeneous cohort sizes (18–261) are a concern |
Key quantitative result: AUC described as "generally favorable" — specific pooled AUC not reported in the abstract, limiting precise effect-size interpretation.
External validation: Meta-analysis design implies aggregation across independent cohorts; individual study heterogeneity is a known limitation.
Main limitation: Small individual study cohorts (some as low as 18 participants); abstract-only access prevents assessment of heterogeneity statistics, model transparency, or imaging modality consistency.
Equity implications: Benefits most available at high-volume stroke centres; rural/low-resource hospitals may lack advanced imaging infrastructure.
Evidence Maturity (confirmed): Validated — meta-analytic evidence supports predictive utility but falls short of guideline-level endorsement.
Article 2 — Zhang et al. — PD-L1 discordance in primary vs. metastatic NSCLC (PMID 42978956)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Directly challenges the clinical assumption that a single PD-L1 biopsy reliably guides immunotherapy eligibility throughout disease course |
| Clinical Relevance | 8 | PD-L1 is the primary biomarker gating checkpoint inhibitor access in NSCLC; discordance has immediate prescribing implications |
| Population Reach | 8 | NSCLC is the leading cause of cancer death globally; millions of patients annually receive PD-L1 testing |
| Implementation Speed | 6 | Implications are actionable now (re-biopsy policy), but guideline bodies and payers must respond; re-biopsy logistics add complexity |
| Evidence Strength | 7 | Meta-analysis of 15 studies, 1,014 matched pairs — reasonable sample; matched-pair design is methodologically appropriate |
Key quantitative result: 1,029 matched primary-metastatic sample pairs; discordance rate magnitude not reported in abstract — a notable gap.
External validation: Multi-study meta-analysis across independent cohorts provides implicit cross-validation.
Main limitation: Abstract-only; discordance rate and direction (primary→metastatic gain or loss of PD-L1) not quantified here, which limits clinical translation specificity.
Equity implications: Re-biopsy requirements could disadvantage patients in low-resource settings or with poor performance status who cannot safely undergo repeat tissue sampling.
Evidence Maturity (confirmed): Validated — evidence strong enough to warrant practice consideration, though formal guideline updates require quantified concordance rates.
Article 3 — Cheng & Liu — Cost-effectiveness of dostarlimab + chemo in NSCLC (PMID 42978095)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Cost-effectiveness modeling of checkpoint inhibitors is established methodology; dostarlimab-specific analysis adds narrow incremental value |
| Clinical Relevance | 6 | Directly informs formulary and coverage decisions in a high-burden cancer; WTP threshold of $150K/QALY is a commonly used but debated benchmark |
| Population Reach | 7 | Metastatic non-squamous NSCLC is a high-volume indication globally |
| Implementation Speed | 5 | Payer adoption requires health technology assessment processes; country-specific WTP thresholds vary considerably |
| Evidence Strength | 5 | Cost-effectiveness analysis (CEA); model quality and input assumptions cannot be evaluated from abstract alone |
Key quantitative result: Total drug cost for dostarlimab + chemo: $366,887 (truncated in abstract); deemed cost-effective at $150K/QALY threshold in the U.S.
Main limitation: Model-based study; conclusions are sensitive to survival input assumptions and drug pricing. Abstract truncates key ICER value.
Equity implications: High drug cost may perpetuate access disparities between insured and uninsured/underinsured patients even if cost-effective at system level.
Evidence Maturity: Validated (modeling context) — useful for payer decisions but not clinical care directly.
Article 4 — Khanal et al. — Transcendental Meditation RCT for cardiometabolic outcomes (PMID 42978240)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Mind-body interventions for cardiometabolic risk are well-trodden; TM-specific RCT evidence in this population adds modest new data |
| Clinical Relevance | 4 | Diastolic BP reduction was small and "non-robust"; no effect on other outcomes limits actionability |
| Population Reach | 5 | Stress-related cardiometabolic risk is universal, but effect size does not support broad prescribing |
| Implementation Speed | 7 | TM is immediately accessible as a lifestyle intervention; no regulatory pathway required |
| Evidence Strength | 6 | RCT design is appropriate; N=65 is underpowered for cardiometabolic endpoints; described as secondary analysis, lowering interpretive weight |
Key quantitative result: Diastolic BP reduction of −1.[X] mmHg (abstract truncated); characterized as "small, non-robust."
Main limitation: Secondary analysis of an RCT (not primary pre-specified endpoint); small N; likely insufficient power for most cardiometabolic outcomes.
Equity implications: TM training requires cost and access to certified instructors — may be inaccessible to lower-income populations.
Evidence Maturity (revised): Exploratory — finding does not meet bar for validated cardiometabolic intervention.
Article 5 — Hu et al. — Dexmedetomidine and postoperative cognitive dysfunction in elderly (PMID 42978121)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | POCD prevention with dexmedetomidine has been studied; this meta-analysis consolidates RCT evidence in a specific surgical context |
| Clinical Relevance | 7 | POCD is common and consequential in elderly surgical patients; a pharmacological prevention strategy is clinically meaningful |
| Population Reach | 7 | Abdominal surgery in the elderly is globally common; aging populations increase relevance |
| Implementation Speed | 7 | DEX is an approved, available anesthetic agent; adoption is an anesthesiologist/protocol decision |
| Evidence Strength | 7 | Meta-analysis of 12 RCTs (N=1,361); RCT-pooling is high-quality design; abstract-only limits heterogeneity assessment |
Key quantitative result: Significant reduction in POCD at postoperative days 1 and 3; reduced TNF-α response. Sample N=1,361 from 14 comparisons.
Main limitation: Effect assessed only at early postoperative timepoints (days 1 and 3); long-term cognitive protection unknown. Only abdominal surgery — generalizability to other surgical types is limited.
Equity implications: DEX is used in well-resourced surgical settings; benefit may not reach elderly patients in resource-limited environments where anesthetic choice is constrained.
Evidence Maturity (confirmed): Validated.
Article 6 — Zhang et al. — Finerenone pharmacovigilance in T2DM-CKD (PMID 42978566)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Real-world safety surveillance of finerenone is timely given recent market entry; dual-database approach (FAERS + JADER) adds methodological value |
| Clinical Relevance | 6 | Identifying new adverse event signals in a widely prescribed drug class is clinically meaningful; hyperkalemia and renal concerns are established |
| Population Reach | 8 | T2DM-CKD is one of the highest-burden comorbidity pairs globally |
| Implementation Speed | 6 | Pharmacovigilance signals require regulatory review before label changes; prescribers may adjust monitoring practices sooner |
| Evidence Strength | 5 | Spontaneous reporting databases (FAERS/JADER) are hypothesis-generating; subject to reporting bias, confounding, and no denominator data |
Key quantitative result: 1,545 (FAERS) and 210 (JADER) finerenone-primary suspect reports identified.
Main limitation: Spontaneous reporting inherently cannot establish causation; underreporting and indication bias are major concerns.
Equity implications: Japanese (JADER) and U.S. (FAERS) databases may not reflect safety profiles in diverse global populations.
Evidence Maturity (revised): Exploratory — pharmacovigilance signals require prospective confirmation.
Article 7 — Gao et al. — Homocysteine redox and HD-MTX nephrotoxicity in leukemia/lymphoma (PMID 42978686)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Hcy redox status as a nephrotoxicity biomarker for HD-MTX is a novel framing; prior work focuses on MTX clearance not Hcy redox forms |
| Clinical Relevance | 6 | Kidney injury from HD-MTX is clinically significant; an early biomarker could allow dose modification or enhanced leucovorin rescue |
| Population Reach | 5 | HD-MTX is used in ALL, lymphoma, osteosarcoma — meaningful but not globally high-volume |
| Implementation Speed | 5 | Homocysteine assays are available; integration into oncology monitoring protocols requires prospective validation |
| Evidence Strength | 4 | Observational study; sample size not fully reported in abstract; correlation-based findings; pediatric vs. adult subgroups add complexity |
Key quantitative result: Hcy/HHcy ratio negatively correlated with creatinine (p<0.0[X]) in pediatric patients — partial truncation in abstract.
Main limitation: Observational design; causality not established; confounding from disease state and concomitant treatments.
Equity implications: Most applicable to pediatric hematologic malignancy centres with laboratory capacity.
Evidence Maturity (revised): Exploratory — observational correlation requires prospective validation.
Article 8 — Zhang et al. — Neoadjuvant chemo vs. CRT vs. chemoimmunotherapy in ESCC (PMID 42978949)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Chemoimmunotherapy as neoadjuvant for ESCC is an emerging area; propensity-score matching improves on simple retrospective comparisons |
| Clinical Relevance | 6 | Resectable ESCC carries a poor prognosis; neoadjuvant strategy selection directly affects surgical outcomes |
| Population Reach | 6 | ESCC predominates in Asia and parts of Africa; globally significant but geographically concentrated |
| Implementation Speed | 5 | Retrospective data; RCT confirmation needed before standard-of-care shift |
| Evidence Strength | 5 | Propensity-score matched retrospective cohort — reduces but cannot eliminate selection bias; sample size not reported in abstract |
Key quantitative result: 1-year RFS significantly lower in nCT group vs. nCRT and nICT groups (p=0.[X]).
Main limitation: Retrospective design; treatment assignment not randomized; surgical quality and centre effects not fully controlled.
Equity implications: Chemoimmunotherapy access may be limited in lower-income countries where ESCC burden is highest.
Evidence Maturity (confirmed): Validated (observational level).
Article 9 — Chen et al. — Bibliometric review of antigen-specific cancer immunotherapy (PMID 42978995)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Bibliometric/knowledge-mapping study; no new clinical or scientific data generated |
| Clinical Relevance | 3 | Indirectly informs field prioritization; no actionable clinical finding |
| Population Reach | 4 | Field overview relevant to researchers and policy makers across oncology broadly |
| Implementation Speed | 2 | No direct translatable finding |
| Evidence Strength | 3 | Bibliometric analysis — methodologically valid for its purpose but lowest rung of primary evidence |
Main limitation: Descriptive; cannot distinguish quality of publications or clinical impact.
Evidence Maturity (revised): Exploratory (field mapping only).
Article 10 — Baggett et al. — Multi-payer cohort for small-area cancer screening estimates (PMID 42981216) 🟡
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Multi-payer claims linkage for sub-state cancer screening surveillance is methodologically innovative and addresses a real data gap |
| Clinical Relevance | 5 | Infrastructure study; not directly changing patient care but enables equity-focused intervention targeting |
| Population Reach | 7 | 12 million+ individuals in NC cohort; framework is exportable to other states |
| Implementation Speed | 5 | Framework must be adopted by state health departments and payers; requires data governance agreements |
| Evidence Strength | 6 | Large cohort (12M individuals, 74.8M person-years); observational/administrative data with known limitations (claims coding errors, coverage gaps) |
Key quantitative result: Parent cohort: 12,010,374 unique individuals; 74,779,932 person-years of follow-up — methodologically impressive scale.
Main limitation: Claims-based; cannot capture uninsured populations (a key equity gap); screening intent vs. receipt may be miscoded.
Equity implications: Explicit goal is identifying geographic disparities; uninsured populations are structurally underrepresented in multi-payer claims, creating a blind spot for the most vulnerable.
Evidence Maturity (confirmed): Validated.
Article 11 — Nie et al. — Plasma IFNL3 for gastric cancer detection in East Asians (PMID 42978105)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | IFNL3 (interferon lambda-3) as a plasma biomarker for gastric cancer is novel; Mendelian randomization adds causal inference layer |
| Clinical Relevance | 6 | Gastric cancer has poor early-detection rates; a blood-based marker could meaningfully shift the detection curve |
| Population Reach | 6 | East Asian populations bear disproportionate GC burden; globally ~1M new cases/year |
| Implementation Speed | 4 | Multiphase validation complete, but regulatory approval and assay standardization required |
| Evidence Strength | 6 | Multiphase validation design with MR analysis (N=395 in validation cohort) — above average for a biomarker study; abstract-only limits full assessment |
Main limitation: East Asian population only; generalizability uncertain. Sample size (395) is modest for a diagnostic validation study.
Equity implications: East Asian-specific finding may inadvertently create diagnostic tools unavailable or unevaluated in other high-risk populations (e.g., Eastern Europe, Latin America).
Evidence Maturity (confirmed): Validated.
Article 12 — Shukla et al. — Social vulnerability and SGLT2i underuse in heart failure (PMID 42978123)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Quantifies SGLT2i access disparities by social vulnerability index — goes beyond prior age/insurance analyses |
| Clinical Relevance | 7 | SGLT2i are guideline-recommended in HFrEF and increasingly HFpEF; underuse in vulnerable communities is a care quality and equity issue |
| Population Reach | 8 | Heart failure affects ~64 million people globally; SGLT2i are broadly applicable |
| Implementation Speed | 7 | Findings directly inform prescribing equity interventions, care management programs, and policy — no regulatory steps needed |
| Evidence Strength | 6 | Large retrospective EHR cohort (389,986 patients); Epic Cosmos cross-institutional database adds generalizability; selection bias from EHR inclusion |
Key quantitative result: 389,986 patients with new HF; 81,387 (20.9%) received SGLT2i — persistent deficit in high-SVI communities.
Main limitation: Retrospective; prescribing decisions may reflect clinical contraindications not captured in SVI; causality cannot be established.
Equity implications: This paper is explicitly about equity — identifies actionable disparities in access to a life-saving drug class by social vulnerability. Central to its value.
Evidence Maturity (confirmed): Validated.
Article 13 — C P et al. — Smartphone facial scanning vs. direct anthropometry (PMID 42978157)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Smartphone 3D scanning validation is an active area; this adds two specific apps (Qlone, Magiscan) to the literature |
| Clinical Relevance | 4 | Primarily relevant to orthodontics and craniofacial assessment; limited oncology or broad clinical impact |
| Population Reach | 4 | Craniofacial measurement is a specialized use case |
| Implementation Speed | 7 | Smartphone apps are immediately deployable in clinical or remote settings |
| Evidence Strength | 5 | Prospective validation with ANOVA; 8/9 parameters meet agreement criteria; sample size not reported in abstract |
Main limitation: Small study implied by sample size not reported; limited to two iOS/Android apps; generalizability to other platforms uncertain.
Evidence Maturity (confirmed): Validated.
Article 14 — Nassr et al. — Management of small U3-U4 thyroid nodules (PMID 42978193)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Thyroid nodule management guidelines exist; this small UK retrospective adds modest local practice data |
| Clinical Relevance | 5 | Avoiding unnecessary biopsies is clinically and economically meaningful |
| Population Reach | 5 | Thyroid nodules are common; <1 cm U3 nodules are frequently found incidentally |
| Implementation Speed | 7 | Practice guideline-aligned; could inform local protocol without regulatory step |
| Evidence Strength | 4 | 81 nodules in 73 patients — very small; retrospective; single-centre UK practice |
Main limitation: Very small N; retrospective; UK-specific U grade classification may not translate to other classification systems (ACR-TIRADS, BETHESDA).
Evidence Maturity (confirmed): Validated (at modest evidence level).
Article 15 — Aloird et al. — French military blood transfusion guideline compliance in Sahel (PMID 42978241)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Military prehospital transfusion compliance studies are niche; limited transferability to civilian practice |
| Clinical Relevance | 4 | Relevant to military medicine specifically; lessons may inform mass casualty civilian protocols |
| Population Reach | 2 | Applies to a small, specific operational context |
| Implementation Speed | 6 | Guideline revision is feasible within military health systems |
| Evidence Strength | 4 | 64 wounded patients receiving 89 BP units — very small; retrospective; single operational theatre |
Main limitation: Extremely small N; single operational context; calls for prospective follow-up before guideline revision.
Evidence Maturity (confirmed): Validated (descriptive compliance assessment only).
Article 16 — Han et al. — Longitudinal HbA1c and polyneuropathy severity (PMID 42978296)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Comparison of mean vs. index HbA1c for neuropathy severity is a focused methodological question with modest clinical implications |
| Clinical Relevance | 5 | Supports the clinical rationale for sustained glycemic control as neuropathy prevention; does not change management |
| Population Reach | 7 | Diabetic neuropathy affects ~50% of people with diabetes worldwide |
| Implementation Speed | 7 | HbA1c is universally measured; using longitudinal mean is a data-available intervention |
| Evidence Strength | 4 | 73 patients from 263 screened; small N; retrospective; "superiority not established" |
Main limitation: Small final sample (73/263); retrospective; inconclusive on the primary comparative question.
Evidence Maturity (revised): Exploratory — findings are hypothesis-generating.
Article 17 — McCloskey et al. — Neuroendocrine proliferations at the GEJ (PMID 42978409)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | GEJ neuroendocrine micronests are undercharacterized; 8% prevalence in unselected biopsies is a potentially practice-informing finding |
| Clinical Relevance | 5 | Pathologists need to recognize these findings to avoid over-diagnosis; clinical management implications are limited |
| Population Reach | 5 | GEJ biopsies are common in reflux/Barrett's work-up populations |
| Implementation Speed | 7 | Recognition by pathologists is immediately actionable via awareness |
| Evidence Strength | 5 | Prospective cohort (66 GEJ biopsies); small but well-designed for a pathologic prevalence study |
Main limitation: Small N (66); single-centre; long-term follow-up data not reported.
Evidence Maturity (confirmed): Validated.
Article 18 — Vollmer et al. — Metabolomics, cognition, and neural networks (PMID 42978722)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Linking metabolomics to cognitive domains and neural networks simultaneously is novel in design |
| Clinical Relevance | 3 | Cognitively normal adults; "limited overlap" in findings; no clinical application at this stage |
| Population Reach | 5 | Cognitive aging is universal concern |
| Implementation Speed | 2 | Basic science discovery; long path to clinical application |
| Evidence Strength | 5 | Observational; mean age 56 (cognitively normal); sample size not reported in abstract |
Main limitation: Cross-sectional observational; limited clinical signal in cognitively normal population; "limited overlap" is a qualified null finding.
Evidence Maturity (revised): Exploratory.
Article 19 — Alexiou et al. — Multi-guideline clinical AI agent for vascular surgery (PMID 42978152)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | RAG-based locked-corpus clinical agent with citation traceability is methodologically interesting; tackles a real usability problem |
| Clinical Relevance | 5 | Point-of-care guideline access could reduce errors; 98% accuracy metric is promising but benchmark design is unclear |
| Population Reach | 5 | Vascular surgery patients globally; tool could be adapted to other surgical specialties |
| Implementation Speed | 5 | Requires EHR integration, institutional validation, and liability frameworks |
| Evidence Strength | 4 | Observational feasibility study; benchmark methodology not fully described in abstract; no clinical outcome data |
Key quantitative result: 98.[X]% accuracy within locked corpus; declined all out-of-scope queries.
Main limitation: No clinical outcome data; benchmark design unclear; hallucination risk outside locked corpus not fully evaluated.
Evidence Maturity (confirmed): Validated (feasibility level).
Articles 20–22 — Korean Aging/Nutrition Cluster (PMIDs 42978349, 42978350, 42978352, 42978354)
These four articles share a thematic cluster from the same journal issue (Korean Journal of Community Nutrition):
| Article | Novelty | Clinical Relevance | Pop. Reach | Impl. Speed | Evidence Strength |
|---|---|---|---|---|---|
| Kim & Hwang — Policy to Fork framework (PMID 42978349) | 4 | 4 | 4 | 4 | 3 |
| Park & Shin — Nutrition education scoping review (PMID 42978350) | 3 | 3 | 3 | 3 | 3 |
| Yang & Kim — Hygiene monitoring in LTC (PMID 42978352) | 3 | 4 | 4 | 5 | 4 |
| Kim & Chung — Low-income vs. general income elderly (PMID 42978354) 🟡 | 4 | 5 | 5 | 4 | 4 |
All four are largely confirmatory policy/health services research with limited generalizability beyond the Korean context. Evidence Maturity: Validated (at descriptive/policy level).
Article 23 — Atagi et al. — Pembrolizumab complete response in Lynch syndrome UTUC (PMID 42978598)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Lynch syndrome-associated UTUC response to pembrolizumab is mechanistically expected but clinically valuable if durable |
| Clinical Relevance | 5 | Single case; hypothesis-generating for a rare indication |
| Population Reach | 2 | Lynch syndrome UTUC is rare (relative to unmet need in this population, score adjusted to 5) |
| Implementation Speed | 4 | Pembrolizumab is available; Lynch syndrome testing increasingly standard |
| Evidence Strength | 2 | Case report; classification_confidence=medium; cannot exceed 5 on Clinical Relevance |
Evidence Maturity (confirmed): Exploratory.
Article 24 — Liu et al. — SMARCA4-deficient uterine sarcoma and ICI (PMID 42978655)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | ICI response without conventional predictive biomarkers (TMB-H, PD-L1, MSI-H) in SDUS challenges established biomarker paradigm |
| Clinical Relevance | 5 | Rare condition; single case; medium confidence |
| Population Reach | 2 | Extremely rare (adjusted to 4 for unmet need) |
| Implementation Speed | 3 | Requires replication before altering practice |
| Evidence Strength | 2 | Case report; medium classification_confidence |
Evidence Maturity (confirmed): Exploratory.
Article 25 — Triggiani et al. — Myeloma relapse mimicking thyroid neoplasia (PMID 42978806)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Intrathyroidal myeloma relapse is rare and diagnostically challenging; case adds to a small literature |
| Clinical Relevance | 5 | Diagnostic vigilance message is clinically actionable for oncologists managing MM patients |
| Population Reach | 3 | Multiple myeloma patients with thyroid nodules — small population |
| Implementation Speed | 7 | Awareness-based change in clinical suspicion threshold |
| Evidence Strength | 2 | Case report; medium confidence |
Evidence Maturity (confirmed): Exploratory.
Article 26 — Wu et al. — CAR-T manufacturing engineering review (PMID 42978867)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Closed manufacturing/ex vivo T-cell expansion advances are active R&D priorities; this review synthesizes rather than discovers |
| Clinical Relevance | 3 | In vitro/review; cannot exceed 5 on Clinical Relevance — capped at 3 (non-human, review context) |
| Population Reach | 6 | CAR-T applies to B-cell malignancies and myeloma — global relevance if manufacturing barriers fall |
| Implementation Speed | 2 | Manufacturing scale-up is a multi-year regulatory and infrastructure challenge |
| Evidence Strength | 3 | In vitro review; not human study |
Evidence Maturity (confirmed): Exploratory.